Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

Clinical trial NCT04813523 · UNKNOWN

Trial details

NCT number: NCT04813523
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Adenocarcinoma of Esophagogastric Junction Neoadjuvant Chemotherapy Pembrolizumab

Start date: 2021-04-01
Primary completion: 2022-03-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.